Close Menu

Pacific Biosciences: Mark Van Oene, Peter Fromen

Pacific Biosciences announced it has appointed Mark Van Oene to the newly created role of chief operating officer and Peter Fromen as chief commercial officer (CCO), both effective Jan. 8, 2021.

Van Oene joins PacBio after 15 years at Illumina, where he most recently served as senior VP and CCO and oversaw worldwide sales and service. He will be responsible for managing PacBio's research, development, and manufacturing organizations and for driving strategic planning and corporate development activities.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.